Comparisons between CUP patients with comorbidities and all cohort patients
| Characteristic . | All patients . | Antiaggregating or anticoagulant therapy . | P . | Splenectomy contraindicated . | P . | Neurologic disorder . | P . | Obesity . | P . |
|---|---|---|---|---|---|---|---|---|---|
| n | 72 | 8 | 20 | 9 | 3 | ||||
| Mean age, y (range) | 63 (20-91) | 71 (63-89) | NS | 69 (29-90) | .021 | 54 (20-80) | NS | 63 (50-74) | NS |
| Male sex, n (%) | 29 (40) | 7 (88) | .003 | 10 (50) | NS | 0 | .01 | 0 | NS |
| ITP duration before romiplostim, y, median (range) | 8.7 (0.1-49) | 14 (2-49) | NS | 5.2 (0-20) | .026 | 14 (0.1-49) | NS | 4 (1-7) | NS |
| Splenectomy, n (%) | 39 (54) | 5 (63) | NS | 0 | NS | 4 (44) | NS | 1 (33) | NS |
| At baseline | |||||||||
| Platelets, × 109/L, mean (range) | 16 (1-60) | 10 (2-20) | NS | 14 (1-60) | NS | 6 (1-15) | .01 | 8 (5-12) | NS |
| Patients with concomitant therapies, n (%) | 48 (67) | 3 (37) | NS | 15 (75) | NS | 7 (78) | NS | 3 (100) | NS |
| Bleeding score, mean (range) | 4.7 (0-46) | 6.4 (0-27) | NS | 2.5 (0-20) | NS | 5.9 (0-15) | NS | 3 (0-7) | NS |
| Primary responders, n (%) | 53 (74) | 6 (75) | NS | 14 (70) | NS | 4 (44) | .048 | 0 | .016 |
| Long-term responders, n (%) | 47 (65) | 6 (75) | NS | 13 (65) | NS | 6 (67) | NS | 1 (33) | NS |
| Characteristic . | All patients . | Antiaggregating or anticoagulant therapy . | P . | Splenectomy contraindicated . | P . | Neurologic disorder . | P . | Obesity . | P . |
|---|---|---|---|---|---|---|---|---|---|
| n | 72 | 8 | 20 | 9 | 3 | ||||
| Mean age, y (range) | 63 (20-91) | 71 (63-89) | NS | 69 (29-90) | .021 | 54 (20-80) | NS | 63 (50-74) | NS |
| Male sex, n (%) | 29 (40) | 7 (88) | .003 | 10 (50) | NS | 0 | .01 | 0 | NS |
| ITP duration before romiplostim, y, median (range) | 8.7 (0.1-49) | 14 (2-49) | NS | 5.2 (0-20) | .026 | 14 (0.1-49) | NS | 4 (1-7) | NS |
| Splenectomy, n (%) | 39 (54) | 5 (63) | NS | 0 | NS | 4 (44) | NS | 1 (33) | NS |
| At baseline | |||||||||
| Platelets, × 109/L, mean (range) | 16 (1-60) | 10 (2-20) | NS | 14 (1-60) | NS | 6 (1-15) | .01 | 8 (5-12) | NS |
| Patients with concomitant therapies, n (%) | 48 (67) | 3 (37) | NS | 15 (75) | NS | 7 (78) | NS | 3 (100) | NS |
| Bleeding score, mean (range) | 4.7 (0-46) | 6.4 (0-27) | NS | 2.5 (0-20) | NS | 5.9 (0-15) | NS | 3 (0-7) | NS |
| Primary responders, n (%) | 53 (74) | 6 (75) | NS | 14 (70) | NS | 4 (44) | .048 | 0 | .016 |
| Long-term responders, n (%) | 47 (65) | 6 (75) | NS | 13 (65) | NS | 6 (67) | NS | 1 (33) | NS |
NS indicates not significant.